Day

November 12, 2019
Predicine and Merck KGaA partner to highlight the importance of multi-parametric profiling of ctDNA and cfRNA for holistic molecular insight for detecting driver mutation, monitoring disease burden and drug resistance in advanced stage colorectal cancer. Predicine, a molecular insights company headquartered in Hayward, California, with global footprints in China, today announced a clinical collaborative study...